BioSpace News Archive

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights, anticipated upcoming milestones, and financial results for the fourth quarter and full year of 2019.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2019 financial and operating results after the close of U.S. financial markets on Monday, March 9, 2020.

Livongo Health, Inc. (NASDAQ: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced financial results for its fourth quarter and full year ended December 31, 2019.

Diversicare Healthcare Services, Inc. (OTCQX:DVCR) today announced that it is scheduled to report financial results for its fourth quarter ended December 31, 2019, on Thursday, March 5, 2020, after the market closes.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2019.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced its fourth quarter financial results for 2019.

Exelixis, Inc. (Nasdaq: EXEL) today announced that George A. Scangos, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors.

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees options to purchase an aggregate of 333,000 shares of BioCryst common stock on February 28, 2020 as inducements material to each employee entering into employment with BioCryst.

BD, a leading global medical technology company, announced that it will present at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020, at 10:45 a.m. ET..